Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program-Reference-Cited by-同舟云学术

Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program

Published:2014-03-19 Issue:12 Volume:120 Page:1818-1829
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ok Chi Young¹,Xu-Monette Zijun Y.¹,Tzankov Alexandar²,O'Malley Dennis P.³,Montes-Moreno Santiago⁴,Visco Carlo⁵,Møller Michael B.⁶,Dybkaer Karen⁷,Orazi Attilio⁸,Zu Youli⁹,Bhagat Govind¹⁰,Richards Kristy L.¹¹,Hsi Eric D.¹²,Han van Krieken J.¹³,Ponzoni Maurilio¹⁴,Farnen John P.¹⁵,Piris Miguel A.⁴,Winter Jane N.¹⁶,Medeiros L. Jeffrey¹,Young Ken H.¹

Affiliation:

1. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Pathology; Basel University Hospital; Basel Switzerland

3. Clarient Pathology Laboratory; Aliso Viejo California

4. Marques de Valdecilla University Hospital; Santander Spain

5. Department of Hematology/Oncology, San Bortolo Hospital; Vicenza Italy

6. Department of Pathology; Odense University Hospital; Odense Denmark

7. Department of Clinical Medicine/Hematology; Aalborg University Hospital; Aalborg Denmark

8. Department of Pathology; Weill Medical College of Cornell University; New York New York

9. Department of Pathology; The Methodist Hospital; Houston Texas

10. Department of Pathology; College of Physicians and Surgeons, Columbia University Medical Center and New York Presbyterian Hospital; New York New York

11. Department of Medicine; University of North Carolina School of Medicine; Chapel Hill North Carolina

12. Department of Clinical Pathology; The Cleveland Clinic; Cleveland Ohio

13. Department of Pathology; Radboud University Nijmegen Medical Center; Nijmegen the Netherlands

14. Department of Pathology; San Raffaele H. Scientific Institute; Milan Italy

15. Department of Hematology/Oncology; Gundersen Lutheran Health System; La Crosse Wisconsin

16. Department of Hematology/Oncology; Feinberg School of Medicine; Northwestern University; Chicago Illinois

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28664/fullpdf

Reference29 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

2. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma;Romaguera;Br J Haematol,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins;Clinical Proteomics;2023-09-13

2. Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses;Cancers;2023-08-02

3. Classification of indolent B-cell lymphomas;Die Pathologie;2023-04-24

4. Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities;Virchows Archiv;2022-12-02

5. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes;Molecular Cancer;2021-10-16